Deals In Depth: January 2013
Gilead licensed rights to four preclinical antibodies from MacroGenics. Stryker bought Chinese device company Trauson for $751 million. Biopharma companies raised double the amount from December, bringing in $2.8 billion, while device funding dropped to $269 million.
You may also be interested in...
In Vivo outlines major trends shaping the top 15 cardiovascular device companies included in the latest Medtech 100 rankings. They include a growing need to reach underserved patient populations, ongoing staffing and other challenges created by the COVID-19 pandemic, and reimbursement obstacles.
While US biosimilar approvals have been thin on the ground in 2021 – with products delayed due to the FDA’s inability to conduct certain facility inspections during the COVID-19 pandemic – the market has nevertheless seen several firsts this year, including two interchangeability designations and the first ophthalmic biosimilar approval.
Novartis has expanded its efforts to help low- and lower-middle-income countries “mitigate the impact of the pandemic and support healthcare systems,” after signing a memorandum of understanding with Vietnam’s Ministry of Health providing various treatments for COVID-19 at-cost.